Essentials of Clinical Radiation Oncology, 2026

Oncology

The document details the 2021 WHO classification of Glioblastoma (GBM), defining it as a grade 4 IDH-wild-type tumor with specific molecular markers and pathological features like microvascular proliferation or necrosis. It highlights GBM's poor prognosis and standard treatment involving maximal safe resection followed by adjuvant radiotherapy and chemotherapy. For Stage III NSCLC, the text emphasizes the heterogeneity of treatment due to varied local and nodal presentations, often influenced by patient performance status. Additionally, it briefly mentions Carcinoma of Unknown Primary in the head and neck, noting its rising incidence, association with HPV, and common presentation as a unilateral neck mass.